

## **Dynamic Contrast Enhanced MRI of the Liver for Therapy Monitoring of Hepatic Metastases from Neuroendocrine Tumors**

**W. H. Sommer<sup>1</sup>, S. Sourbron<sup>2</sup>, M. F. Reiser<sup>1</sup>, K. A. Herrmann<sup>1</sup>, and C. Zech<sup>1</sup>**

<sup>1</sup>Department of Radiology, University Hospital Munich, Grosshadern Campus, Munich, Bavaria, Germany, <sup>2</sup>University of Leeds, Leeds, United Kingdom

### **Introduction:**


Liver metastases of neuroendocrine tumors (NET) are hypervascular in the arterial dominant phase (1;2). The response of the metastases to treatment is not sufficiently reflected by the RECIST criteria. Therefore, PET-CT is typically used for treatment follow-up, rather than MRI. The aim of the current study was to analyze perfusion parameters from dynamic contrast enhanced MRI (DCE-MRI) using a dual-inlet two-compartment uptake model for liver specific MRI contrast agent Gd-EOB-DTPA. These parameters should be correlated with specific uptake values (SUV) derived from PET-CT imaging with the somatostatin-receptor specific tracer Gallium-Dotatate.

### **Material and Methods:**

Dynamic contrast enhanced-MRI data were acquired at 3T (Siemens Verio) in 18 patients with proven metastases of NET using the 3D gradient-echo sequence TWIST (48 coronal slices, 4mm thickness, 192x192 matrix, 2.1sec temporal resolution, 5min acquisition). All patients underwent MRI for clinical reasons. A standard dose of Gd-EOB-DTPA (flow: 2ml/min; 25 $\mu$ mol/kg BW; Primovist, Bayer) was used. These patients also underwent PET-CT with the somatostatin-receptor specific PET-tracer Ga-Dotatate within 1 week after MRI. By visual coregistration ROIs were placed in all hepatic metastases ( $>3$ cm) which were visible both on PET-CT and MRI images. Additionally one ROI was placed in non-metastatic normal appearing liver tissue (NALT) both in DCE-MRI and PET-CT datasets. DCE-MRI parameters (arterial and venous plasma flow, extracellular mean transit time, extracellular volume and intracellular uptake rate of Gd-EOB-DTPA) and corrected SUV<sub>max</sub> (SUV<sub>max</sub><sub>metastasis</sub> / SUV<sub>max</sub><sub>NALT</sub>) values from PET-CT datasets were computed for all ROIs using an inhouse costumized software (PMI 0.4). Pearson's correlation coefficient was calculated for DCE-MRI parameters (r) and SUV<sub>max</sub> values.

### **Results:**

A total of 62 ROIs was placed in hepatic metastases of NET. Mean diameter of ROIs was 3.8cm. Arterial plasma flow showed highest correlation values with Ga-Dotatate uptake ( $r=0.74$ ;  $p<0.0001$ ; 95%CI: 0.57 to 0.88) followed by extracellular volume ( $r=0.42$ ;  $p=0.020$ ; 95%CI: 0.09 to 0.68) (see figure 1). Venous plasma flow ( $r=-0.15$ ;  $p=0.42$ ; 95%CI: -0.49 to 0.22), extracellular mean transit time ( $r=-0.33$ ;  $p=0.08$ ; 95%CI: -0.62 to 0.04) and intracellular uptake rate of Gd-EOB-DTPA ( $r=-0.20$ ;  $p=0.29$ ; 95%CI: -0.53 to 0.17) were not significantly correlated to SUV<sub>max</sub>.



**Figure 1: Exemplary case of liver metastases of NET before therapy:**

Left: Coronary PET-CT with the somatostatin-receptor specific PET-CT tracer Ga-Dotatate.

Right: Parameter Map using dynamic-contrast enhanced MRI. This coronary view of the liver shows the arterial plasma flow for the large metastasis in segment V/VIII of the right liver lobe and the good correlation between SUV-values and the arterial plasma flow both in the hypervascularized rim and the necrotic center of the metastasis.

### **Conclusion:**

MRI-perfusion parameters from the dual-inlet two-compartment uptake model provide functional information for liver metastases of neuroendocrine tumors. Especially arterial plasma flow shows a high correlation with SUV-values derived from the somatostatin-receptor specific PET tracer Ga-Dotatate. For patients with hypervascularized liver metastases, DCE-MRI provides additional functional information which might be relevant for therapy monitoring.

### **Reference List**

1. Rockall AG, Reznek RH (2007) Imaging of neuroendocrine tumours (CT/MR/US). Best Pract Res Clin Endocrinol Metab 21: 43-68.
2. Sundin A, Garske U, Orlefors H (2007) Nuclear imaging of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 21: 69-85.
3. S. Sourbron, W. Sommer, C. Zech, M. Reiser, K. Herrmann (2009); Tracer-kinetic analysis of Gd-EOB-DTPA in the liver with a dual-inlet two-compartment uptake model; ISMRM